Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia

Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new appro...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia Research and Treatment 2012-01, Vol.2012 (2012), p.224-234
Main Authors: Brown, Geoffrey, Hughes, Philip J.
Format: Article
Language:English
Subjects:
Age
Apoptosis
Cancer therapies
Cell cycle
Genes
Leukemia
Older people
Population
Prostate cancer
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053
cites cdi_FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053
container_end_page 234
container_issue 2012
container_start_page 224
container_title Leukemia Research and Treatment
container_volume 2012
creator Brown, Geoffrey
Hughes, Philip J.
description Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells resulting in these cells having a limited lifespan. Differentiation therapy also offers the prospect of a less aggressive treatment by virtue of attenuated growth of leukemia cells coupled to limited damage to normal cells. The success of ATRA in differentiation therapy of APL is well known. However, ATRA does not work in non-APL AML. Here we examine some of the molecular pathways towards new retinoid-based differentiation therapy of non-APL AML. Prospects include modulation of the epigenetic status of ATRA-insensitive AML cells, agents that influence intracellular signalling events that are provoked by ATRA, and the use of novel synthetic retinoids.
doi_str_mv 10.1155/2012/939021
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><airiti_id>P20151217005_201212_201711150018_201711150018_224_234</airiti_id><sourcerecordid>2877337781</sourcerecordid><originalsourceid>FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhiNERavSE2dQJC6oaNvx2E6cS6Vq-aq6CITK2fImY9YliRc7odp_j6OUBXrBl7FnHr9-x5NlzxicMSblOQLD84pXgOxRdoRQwYIjlo_3e1YdZicx3kJapQAEfJIdYspzKflRdv2FBtd71-RvnLUUqB-cGZzv85sNBbPd5daHfOm7bkrtthRzb_PLehwo_7ijdrq5ovE7dc48zQ6saSOd3Mfj7Ou7tzfLD4vVp_dXy8vVwnAFbFELg2srK7S1karAkiyklMDCEKFiggta14rVFSgjDRBvOLeFKgvkRQOSH2cXs-52XHfU1MlzMK3eBteZsNPeOP1vpXcb_c3_1FyCQMQk8OpeIPgfI8VBdy7W1LamJz9GzRIjOAihEvryAXrrx9Cn9hKlkDPkwBP1eqbq4GMMZPdmGOhpTnqak57nlOgXf_vfs7-nkoDTGdi4vjF37j9qz2eYEkLW7GEJlYKp2dVcNy64wf3x_zmpSIasBJgVk2YKJUtPADD14IBCT7_yC4tftnk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1282312303</pqid></control><display><type>article</type><title>Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central (Training)</source><source>Wiley Open Access</source><creator>Brown, Geoffrey ; Hughes, Philip J.</creator><contributor>Studzinski, George P.</contributor><creatorcontrib>Brown, Geoffrey ; Hughes, Philip J. ; Studzinski, George P.</creatorcontrib><description>Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells resulting in these cells having a limited lifespan. Differentiation therapy also offers the prospect of a less aggressive treatment by virtue of attenuated growth of leukemia cells coupled to limited damage to normal cells. The success of ATRA in differentiation therapy of APL is well known. However, ATRA does not work in non-APL AML. Here we examine some of the molecular pathways towards new retinoid-based differentiation therapy of non-APL AML. Prospects include modulation of the epigenetic status of ATRA-insensitive AML cells, agents that influence intracellular signalling events that are provoked by ATRA, and the use of novel synthetic retinoids.</description><identifier>ISSN: 2090-3219</identifier><identifier>EISSN: 2090-3227</identifier><identifier>DOI: 10.1155/2012/939021</identifier><identifier>PMID: 23213553</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Age ; Apoptosis ; Cancer therapies ; Cell cycle ; Genes ; Leukemia ; Older people ; Population ; Prostate cancer ; Review</subject><ispartof>Leukemia Research and Treatment, 2012-01, Vol.2012 (2012), p.224-234</ispartof><rights>Copyright © 2012 Geoffrey Brown and Philip Hughes.</rights><rights>Copyright © 2012 Geoffrey Brown and Philip Hughes. Geoffrey Brown et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2012 G. Brown and P. Hughes. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053</citedby><cites>FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1282312303/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1282312303?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23213553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Studzinski, George P.</contributor><creatorcontrib>Brown, Geoffrey</creatorcontrib><creatorcontrib>Hughes, Philip J.</creatorcontrib><title>Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia</title><title>Leukemia Research and Treatment</title><addtitle>Leuk Res Treatment</addtitle><description>Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells resulting in these cells having a limited lifespan. Differentiation therapy also offers the prospect of a less aggressive treatment by virtue of attenuated growth of leukemia cells coupled to limited damage to normal cells. The success of ATRA in differentiation therapy of APL is well known. However, ATRA does not work in non-APL AML. Here we examine some of the molecular pathways towards new retinoid-based differentiation therapy of non-APL AML. Prospects include modulation of the epigenetic status of ATRA-insensitive AML cells, agents that influence intracellular signalling events that are provoked by ATRA, and the use of novel synthetic retinoids.</description><subject>Age</subject><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Genes</subject><subject>Leukemia</subject><subject>Older people</subject><subject>Population</subject><subject>Prostate cancer</subject><subject>Review</subject><issn>2090-3219</issn><issn>2090-3227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqFkU1v1DAQhiNERavSE2dQJC6oaNvx2E6cS6Vq-aq6CITK2fImY9YliRc7odp_j6OUBXrBl7FnHr9-x5NlzxicMSblOQLD84pXgOxRdoRQwYIjlo_3e1YdZicx3kJapQAEfJIdYspzKflRdv2FBtd71-RvnLUUqB-cGZzv85sNBbPd5daHfOm7bkrtthRzb_PLehwo_7ijdrq5ovE7dc48zQ6saSOd3Mfj7Ou7tzfLD4vVp_dXy8vVwnAFbFELg2srK7S1karAkiyklMDCEKFiggta14rVFSgjDRBvOLeFKgvkRQOSH2cXs-52XHfU1MlzMK3eBteZsNPeOP1vpXcb_c3_1FyCQMQk8OpeIPgfI8VBdy7W1LamJz9GzRIjOAihEvryAXrrx9Cn9hKlkDPkwBP1eqbq4GMMZPdmGOhpTnqak57nlOgXf_vfs7-nkoDTGdi4vjF37j9qz2eYEkLW7GEJlYKp2dVcNy64wf3x_zmpSIasBJgVk2YKJUtPADD14IBCT7_yC4tftnk</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Brown, Geoffrey</creator><creator>Hughes, Philip J.</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia</title><author>Brown, Geoffrey ; Hughes, Philip J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Age</topic><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Genes</topic><topic>Leukemia</topic><topic>Older people</topic><topic>Population</topic><topic>Prostate cancer</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, Geoffrey</creatorcontrib><creatorcontrib>Hughes, Philip J.</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia Research and Treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, Geoffrey</au><au>Hughes, Philip J.</au><au>Studzinski, George P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia</atitle><jtitle>Leukemia Research and Treatment</jtitle><addtitle>Leuk Res Treatment</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>224</spage><epage>234</epage><pages>224-234</pages><issn>2090-3219</issn><eissn>2090-3227</eissn><abstract>Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells resulting in these cells having a limited lifespan. Differentiation therapy also offers the prospect of a less aggressive treatment by virtue of attenuated growth of leukemia cells coupled to limited damage to normal cells. The success of ATRA in differentiation therapy of APL is well known. However, ATRA does not work in non-APL AML. Here we examine some of the molecular pathways towards new retinoid-based differentiation therapy of non-APL AML. Prospects include modulation of the epigenetic status of ATRA-insensitive AML cells, agents that influence intracellular signalling events that are provoked by ATRA, and the use of novel synthetic retinoids.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>23213553</pmid><doi>10.1155/2012/939021</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-3219
ispartof Leukemia Research and Treatment, 2012-01, Vol.2012 (2012), p.224-234
issn 2090-3219
2090-3227
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504222
source Publicly Available Content (ProQuest); PubMed Central (Training); Wiley Open Access
subjects Age
Apoptosis
Cancer therapies
Cell cycle
Genes
Leukemia
Older people
Population
Prostate cancer
Review
title Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A12%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retinoid%20Differentiation%20Therapy%20for%20Common%20Types%20of%20Acute%20Myeloid%20Leukemia&rft.jtitle=Leukemia%20Research%20and%20Treatment&rft.au=Brown,%20Geoffrey&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=224&rft.epage=234&rft.pages=224-234&rft.issn=2090-3219&rft.eissn=2090-3227&rft_id=info:doi/10.1155/2012/939021&rft_dat=%3Cproquest_pubme%3E2877337781%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a3801-c4a2bf592fca58627ef04a2426aee281434ebc81c908a5a0e3d33f6876236d053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1282312303&rft_id=info:pmid/23213553&rft_airiti_id=P20151217005_201212_201711150018_201711150018_224_234&rfr_iscdi=true